Quantifying the difference in risk of adverse events by induction treatment regimen in pediatric acute lymphoblastic leukemia

References

• Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015;373(16):1541–1552.
   PubMed Web of Science ®Google Scholar
• Cooper SL, Brown PA. Treatment of pediatric acute lymphoblastic leukemia. Pediatr Clin North Am. 2015;62(1):61–73.
   PubMed Web of Science ®Google Scholar
• Moricke A, Zimmermann M, Valsecchi MG, et al. Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000. Blood. 2016;127(17):2101–2112.
   PubMed Web of Science ®Google Scholar
• Lund B, Asberg A, Heyman M, et al. Risk factors for treatment related mortality in childhood acute lymphoblastic leukaemia. Pediatr Blood Cancer. 2011;56(4):551–559.
   PubMed Web of Science ®Google Scholar
• Denton CC, Rawlins YA, Oberley MJ, et al. Predictors of hepatotoxicity and pancreatitis in children and adolescents with acute lymphoblastic leukemia treated according to contemporary regimens. Pediatr Blood Cancer. 2018;65(3):e26891.
   Web of Science ®Google Scholar
• Koltin D, Sung L, Naqvi A, et al. Medication induced diabetes during induction in pediatric acute lymphoblastic leukemia: prevalence, risk factors and characteristics. Support Care Cancer. 2012;20(9):2009–2015.
   PubMed Web of Science ®Google Scholar
• Yeshayahu Y, Koltin D, Hamilton J, et al. Medication-induced diabetes during induction treatment for ALL, an early marker for future metabolic risk? Pediatr Diabetes. 2015;16(2):104–108.
   PubMed Web of Science ®Google Scholar
• Millan NC, Pastrana A, Guitter MR, et al. Acute and sub-acute neurological toxicity in children treated for acute lymphoblastic leukemia. Leuk Res. 2018;65:86–93.
   PubMed Web of Science ®Google Scholar
• Wilkes JJ, Hennessy S, Xiao R, et al. Volume–outcome relationships in pediatric acute lymphoblastic leukemia: association between hospital pediatric and pediatric oncology volume with mortality and intensive care resources during initial therapy. Clin Lymphoma Myeloma Leuk. 2016;16(7):404–410e1.
   PubMed Web of Science ®Google Scholar
• Moghrabi A, Levy DE, Asselin B, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood. 2007;109(3):896–904.
   PubMed Web of Science ®Google Scholar
• Jastaniah W, Elimam N, Abdalla K, et al. Identifying causes of variability in outcomes in children with acute lymphoblastic leukemia treated in a resource-rich developing country. Pediatr Blood Cancer. 2015;62(6):945–950.
   PubMed Web of Science ®Google Scholar
• Lee JW, Kim SK, Jang PS, et al. Treatment of children with acute lymphoblastic leukemia with risk group based intensification and omission of cranial irradiation: a Korean study of 295 patients. Pediatr Blood Cancer. 2016;63(11):1966–1973.
   PubMed Web of Science ®Google Scholar
• Afzal S, Ethier MC, Dupuis LL, et al. Risk factors for infection-related outcomes during induction therapy for childhood acute lymphoblastic leukemia. Pediatr Infect Dis J. 2009;28(12):1064–1068.
   PubMed Web of Science ®Google Scholar
• Rytting ME, Jabbour EJ, Jorgensen JL, et al. Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen. Am J Hematol. 2016;91(8):819–823.
   PubMed Web of Science ®Google Scholar
• Wolf J, Tang L, Flynn PM, et al. Levofloxacin prophylaxis during induction therapy for pediatric acute lymphoblastic leukemia. Clin Infect Dis. 2017;65(11):1790–1798.
   PubMed Web of Science ®Google Scholar
• Inaba H, Pei D, Wolf J, et al. Infection-related complications during treatment for childhood acute lymphoblastic leukemia. Ann Oncol. 2017;28(2):386–392.
   PubMed Web of Science ®Google Scholar
• Bergmann K, Hasle H, Asdahl P, et al. Central venous catheters and bloodstream infection during induction therapy in children with acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2016;38(3):e82–e87.
   PubMed Web of Science ®Google Scholar
• Katsibardi K, Papadakis V, Charisiadou A, et al. Blood stream infections through the entire course of acute lymphoblastic leukemia treatment. Neoplasma. 2011;58(4):326–330.
   PubMed Web of Science ®Google Scholar
• Grace RF, Dahlberg SE, Neuberg D, et al. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol. 2011;152(4):452–459.
   PubMed Web of Science ®Google Scholar
• Qureshi A, Mitchell C, Richards S, et al. Asparaginase-related venous thrombosis in UKALL 2003- re-exposure to asparaginase is feasible and safe. Br J Haematol. 2010;149(3):410–413.
   PubMed Web of Science ®Google Scholar
• Farinasso L, Bertorello N, Garbarini L, et al. Risk factors of central venous lines-related thrombosis in children with acute lymphoblastic leukemia during induction therapy: a prospective study. Leukemia. 2007;21(3):552–556.
   PubMed Web of Science ®Google Scholar
• Caruso V, Iacoviello L, Di Castelnuovo A, et al. Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood. 2006;108(7):2216–2222.
   PubMed Web of Science ®Google Scholar
• Prasca S, Carmona R, Ji L, et al. Obesity and risk for venous thromboembolism from contemporary therapy for pediatric acute lymphoblastic leukemia. Thromb Res. 2018;165:44–50.
   PubMed Web of Science ®Google Scholar
• Couturier MA, Huguet F, Chevallier P, et al. Cerebral venous thrombosis in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma during induction chemotherapy with l-asparaginase: the GRAALL experience. Am J Hematol. 2015;90(11):986–991.
   PubMed Web of Science ®Google Scholar
• Grace RF, DeAngelo DJ, Stevenson KE, et al. The use of prophylactic anticoagulation during induction and consolidation chemotherapy in adults with acute lymphoblastic leukemia. J Thromb Thrombolysis. 2018;45(2):306–314.
   PubMed Web of Science ®Google Scholar
• Cetin M, Yetgin S, Kara A, et al. Hyperglycemia, ketoacidosis and other complications of l-asparaginase in children with acute lymphoblastic leukemia. J Med. 1994;25(3–4):219–229.
   PubMedGoogle Scholar
• Sonabend RY, McKay SV, Okcu MF, et al. Hyperglycemia during induction therapy is associated with poorer survival in children with acute lymphocytic leukemia. J Pediatr. 2009;155(1):73–78.
   PubMed Web of Science ®Google Scholar
• Lowas SR, Marks D, Malempati S. Prevalence of transient hyperglycemia during induction chemotherapy for pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer. 2009;52(7):814–818.
   PubMed Web of Science ®Google Scholar
• Baillargeon J, Langevin AM, Mullins J, et al. Transient hyperglycemia in Hispanic children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2005;45(7):960–963.
   PubMed Web of Science ®Google Scholar
• Treepongkaruna S, Thongpak N, Pakakasama S, et al. Acute pancreatitis in children with acute lymphoblastic leukemia after chemotherapy. J Pediatr Hematol Oncol. 2009;31(11):812–815.
   PubMed Web of Science ®Google Scholar
• Wedekind MF, Dennis R, Sturm M, et al. The effects of hospital length of stay on readmissions for children with newly diagnosed acute lymphoblastic leukemia. J Pediatr Hematol/Oncol. 2016;38(5):329–333.
   PubMed Web of Science ®Google Scholar
• Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13(3):176–181.
   PubMed Web of Science ®Google Scholar
• Miller TP, Fisher BT, Getz KD, et al. Unintended consequences of evolution of the common terminology criteria for adverse events. Pediatr Blood Cancer. 2019;66(7):e27747.
   PubMed Web of Science ®Google Scholar
• NCI. National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v5.0; 2017. Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm
   Google Scholar
• Miller TP, Li Y, Kavcic M, et al. Accuracy of adverse event ascertainment in clinical trials for pediatric acute myeloid leukemia. J Clin Oncol. 2016;34(13):1537–1543.
   PubMed Web of Science ®Google Scholar
• Alexander S, Fisher BT, Gaur AH, et al. Effect of levofloxacin prophylaxis on bacteremia in children with acute leukemia or undergoing hematopoietic stem cell transplantation: a randomized clinical trial. JAMA. 2018;320(10):995–1004.
   PubMed Web of Science ®Google Scholar
• Kern WV, Klose K, Jellen-Ritter AS, et al. Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis. 2005;24(2):111–118.
   PubMed Web of Science ®Google Scholar
• Gregoriou K, Craigie I, Gibson B, et al. Risk factors and management of corticosteroid-induced hyperglycaemia in paediatric acute lymphoblastic leukaemia. Pediatr Blood Cancer. 2020;67(2):e28085.
   PubMed Web of Science ®Google Scholar
• Gaynon PS, Trigg ME, Heerema NA, et al. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983–1995. Leukemia. 2000;14(12):2223–2233.
   PubMed Web of Science ®Google Scholar
• Kamal N, Koh C, Samala N, et al. Asparaginase-induced hepatotoxicity: rapid development of cholestasis and hepatic steatosis. Hepatol Int. 2019;13(5):641–648.
   PubMed Web of Science ®Google Scholar
• Li L, Jick S, Breitenstein S, et al. Prevalence of diabetes and diabetic nephropathy in a large U.S. commercially insured pediatric population, 2002–2013. Diabetes Care. 2016;39(2):278–284.
   PubMed Web of Science ®Google Scholar